In vitro metabolism of thyroxine by rat and human hepatocytes

Xenobiotica

Volumn 44, Issue 5, 2014, Pages 391-403

  Richardson, Vicki M ^a,b   Ferguson, Stephen S ^c   Sey, Yusupha M ^a   Devito, Michael J ^d  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c Life Technologies Corp   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Deiodination; Glucuronidation; PCB 153; Sulfation; T4; Thyroid hormone

Indexed keywords

2,2',4,4',5,5' HEXACHLOROBIPHENYL; 3 3 5 TRIIODOTHYRONINE; LIOTHYRONINE; THYROXINE; UNCLASSIFIED DRUG; 2,4,5,2',4',5'-HEXACHLOROBIPHENYL; POLYCHLORINATED BIPHENYL;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; GLUCURONIDATION; HUMAN; HUMAN CELL; INCUBATION TIME; LIVER; LIVER CELL; LIVER CLEARANCE; LIVER METABOLISM; METABOLITE; MICROSOME; NONHUMAN; RAT; SANDWICH CULTURED HEPATOCYTE; THYROXINE METABOLISM; AGED; ANIMAL; CELL CULTURE; CULTURE TECHNIQUE; DRUG EFFECTS; DRUG INACTIVATION; FEMALE; LIVER MICROSOME; MALE; METABOLISM; MIDDLE AGED; SPECIES DIFFERENCE; SPRAGUE DAWLEY RAT; TIME; YOUNG ADULT;

AGED; ANIMALS; CELL CULTURE TECHNIQUES; CELLS, CULTURED; FEMALE; HEPATOCYTES; HUMANS; INACTIVATION, METABOLIC; MALE; MICROSOMES, LIVER; MIDDLE AGED; POLYCHLORINATED BIPHENYLS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; THYROXINE; TIME FACTORS; YOUNG ADULT;

EID: 84898733609     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2013.847990     Document Type: Article

References (65)

1. Barter RA, Klaassen CD. (1992). UDP-glucuronosyltransferase inducers reduce thyroid hormone levels in rats by an extrathyroidal mechanism. Toxicol Appl Pharmacol 113:36-42.
2. Bastomsky CH. (1974). Effects of a polychlorinated biphenyl mixture (aroclor 1254) and DDT on biliary thyroxine excretion in rats. Endocrinology 95:1150-5.
3. Bayliss MK, Bell JA, Jenner WN, et al. (1999). Utility of hepatocytes to model species differences in the metabolism of loxtidine and to predict pharmacokinetic parameters in rat, dog and man. Xenobiotica 29:253-68.
4. Benedetti MS, Whomsley R, Baltes E, Tonner F. (2005). Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferase induction. Eur J Clin Pharmacol 61:863-72.
5. Blondeau JP, Osty J, Francon J. (1988). Characterization of the thyroid hormone transport system of isolated hepatocytes. J Biol Chem 263: 2685-92.
6. Bort R, Ponsoda X, Carrasco E, et al. (1996a). Comparative metabolism of the nonsteroidal antiinflammatory drug, aceclofenac, in the rat, monkey, and human. Drug Metab Dispos 24:969-75.
7. Bort R, Ponsoda X, Carrasco E, et al. (1996b). Metabolism of aceclofenac in humans. Drug Metab Dispos 24:834-41.
8. Craft ES, DeVito MJ, Crofton KM. (2002). Comparative responsiveness of hypothyroxinemia and hepatic enzyme induction in Long-Evans rats versus C57BL/6J mice exposed to TCDD-like and phenobarbital-like polychlorinated biphenyl congeners. Toxicol Sci 68:372-80.
9. Crofton KM, Craft ES, Hedge JM, et al. (2005). Thyroid-hormonedisrupting chemicals: evidence for dose-dependent additivity or synergism. Environ Health Perspect 113:1549-54.
10. Davies PH, Sheppard MC, Franklyn JA. (1996). Regulation of type I 50-deiodinase by thyroid hormone and dexamethasone in rat liver and kidney cells. Thyroid 6:221-8.
11. De Jong M, Docter R, Van Der Hoek HJ, et al. (1992). Transport of 3,5,30-triiodothyronine into the perfused rat liver and subsequent metabolism are inhibited by fasting. Endocrinology 131: 463-70.
12. de Jong M, Visser TJ, Bernard BF, et al. (1993). Transport and metabolism of iodothyronines in cultured human hepatocytes. J Clin Endocrinol Metab 77:139-43.
13. DeVito M, Biegel L, Brouwer A, et al. (1999). Screening methods for thyroid hormone disruptors. Environ Health Perspect 107: 407-15.
14. Friesema EC, Docter R, Moerings EP, et al. (1999). Identification of thyroid hormone transporters. Biochem Biophys Res Commun 254: 497-501.
15. Friesema EC, Ganguly S, Abdalla A, et al. (2003). Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J Biol Chem 278:40128-35.
16. Friesema EC, Jansen J, Jachtenberg JW, et al. (2008). Effective cellular uptake and efflux of thyroid hormone by human monocarboxylate transporter 10. Mol Endocrinol 22:1357-69.
17. Ganem LG, Trottier E, Anderson A, Jefcoate CR. (1999). Phenobarbital induction of CYP2B1/2 in primary hepatocytes: endocrine regulation and evidence for a single pathway for multiple inducers. Toxicol Appl Pharmacol 155:32-42.
18. Hagmar L, Rylander L, Dyremark E, et al. (2001). Plasma concentrations of persistent organochlorines in relation to thyrotropin and thyroid hormone levels in women. Int Arch Occup Environ Health 74: 184-8.
19. He P, Wang A, Niu Q, et al. (2011). Toxic effect of PBDE-47 on thyroid development, learning, and memory, and the interaction between PBDE-47 and PCB153 that enhances toxicity in rats. Toxicol Ind Health 27:279-88.
20. Hewitt NJ, Buhring KU, Dasenbrock J, et al. (2001). Studies comparing in vivo:in vitro metabolism of three pharmaceutical compounds in rat, dog, monkey, and human using cryopreserved hepatocytes, microsomes, and collagen gel immobilized hepatocyte cultures. Drug Metab Dispos 29:1042-50.
21. Hewitt NJ, Lechon MJ, Houston JB, et al. (2007a). Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159-234.
22. Hewitt NJ, Lecluyse EL, Ferguson SS. (2007b). Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica 37:1196-224.
23. Hoffmaster KA, Turncliff RZ, LeCluyse EL, et al. (2004). P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: relevance to the hepatobiliary disposition of a model opioid peptide. Pharm Res 21:1294-302.
24. Hood A, Allen ML, Liu Y, et al. (2003). Induction of T(4) UDP-GT activity, serum thyroid stimulating hormone, and thyroid follicular cell proliferation in mice treated with microsomal enzyme inducers. Toxicol Appl Pharmacol 188:6-13.
25. Hood A, Hashmi R, Klaassen CD. (1999). Effects of microsomal enzyme inducers on thyroid-follicular cell proliferation, hyperplasia, and hypertrophy. Toxicol Appl Pharmacol 160:163-70.
26. Hood A, Klaassen CD. (2000a). Differential effects of microsomal enzyme inducers on in vitro thyroxine (T(4)) and triiodothyronine (T(3)) glucuronidation. Toxicol Sci 55:78-84.
27. Hood A, Klaassen CD. (2000b). Effects of microsomal enzyme inducers on outer-ring deiodinase activity toward thyroid hormones in various rat tissues. Toxicol Appl Pharmacol 163:240-8.
28. Jansen J, Friesema EC, Milici C, Visser TJ. (2005). Thyroid hormone transporters in health and disease. Thyroid 15:757-68.
29. Kaptein E, van Haasteren GA, Linkels E, et al. (1997). Characterization of iodothyronine sulfotransferase activity in rat liver. Endocrinology 138:5136-43.
30. Kato Y, Ikushiro S, Emi Y, et al. (2008). Hepatic UDP- glucuronosyltransferases responsible for glucuronidation of thyroxine in humans. Drug Metab Dispos 36:51-5.
31. Kester MH, Kaptein E, Roest TJ, et al. (1999). Characterization of human iodothyronine sulfotransferases. J Clin Endocrinol Metab 84: 1357-64.
32. Kester MH, Kaptein E, Roest TJ, et al. (2003). Characterization of rat iodothyronine sulfotransferases. Am J Physiol Endocrinol Metab 285: E592-8.
33. Klaassen CD, Hood AM. (2001). Effects of microsomal enzyme inducers on thyroid follicular cell proliferation and thyroid hormone metabolism. Toxicol Pathol 29:34-40.
34. Kolaja KL, Klaassen CD. (1998). Dose-response examination of UDPglucuronosyltransferase inducers and their ability to increase both TGF-beta expression and thyroid follicular cell apoptosis. Toxicol Sci 46:31-7.
35. Krenning E, Docter R, Bernard B, et al. (1981). Characteristics of active transport of thyroid hormone into rat hepatocytes. Biochim Biophys Acta 676:314-20.
36. LeCluyse EL. (2001). Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 13:343-68.
37. LeCluyse E, Madan A, Hamilton G, et al. (2000). Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J Biochem Mol Toxicol 14:177-88.
38. Li X, Anderson RJ. (1999). Sulfation of iodothyronines by recombinant human liver steroid sulfotransferases. Biochem Biophys Res Commun 263:632-9.
39. Liu J, Liu Y, Barter RA, Klaassen CD. (1995). Alteration of thyroid homeostasis by UDP-glucuronosyltransferase inducers in rats: a doseresponse study. J Pharmacol Exp Ther 273:977-85.
40. Malik R, Hodgson H. (2002). The relationship between the thyroid gland and the liver. QJM 95:559-69.
41. Martin LA, Wilson DT, Reuhl KR, et al. (2012). Polychlorinated biphenyl congeners that increase the glucuronidation and biliary excretion of thyroxine are distinct from the congeners that enhance the serum disappearance of thyroxine. Drug Metab Dispos 40:588-95.
42. McClain RM, Levin AA, Posch R, Downing JC. (1989). The effect of phenobarbital on the metabolism and excretion of thyroxine in rats. Toxicol Appl Pharmacol 99:216-28.
43. Mitchell AM, Tom M, Mortimer RH. (2005). Thyroid hormone export from cells: contribution of P-glycoprotein. J Endocrinol 185:93-8.
44. NHANES. (2008). National Health and Nutrition Examination Survey Home Page Centers for Disease Control and Prevention, National Center for Health Statistics, Atlanta, GA. Available from: http://www.cdc.gov/nchs/nhanes.htm [last accessed May 2012].
45. Obach RS. (1997). Nonspecific binding to microsomes: impact on scaleup of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos 25:1359-69.
46. Ohnhaus EE, Studer H. (1983). A link between liver microsomal enzyme activity and thyroid hormone metabolism in man. Br J Clin Pharmacol 15:71-6.
47. Oppenheimer JH, Bernstein G, Surks MI. (1968). Increased thyroxine turnover and thyroidal function after stimulation of hepatocellular binding of thyroxine by phenobarbital. J Clin Invest 47:1399-406.
48. Pizzagalli F, Hagenbuch B, Stieger B, et al. (2002). Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol 16:2283-96.
49. Ponsoda X, Pareja E, Gomez-Lechon MJ, et al. (2001). Drug biotransformation by human hepatocytes. In vitro/in vivo metabolism by cells from the same donor. J Hepatol 34:19-25.
50. Rutgers M, Bonthuis F, de Herder WW, Visser TJ. (1987). Accumulation of plasma triiodothyronine sulfate in rats treated with propylthiouracil. J Clin Invest 80:758-62.
51. Rutgers M, Pigmans IG, Bonthuis F, et al. (1989). Effects of propylthiouracil on the biliary clearance of thyroxine (T4) in rats: decreased excretion of 3,5,30-triiodothyronine glucuronide and increased excretion of 3,30,50-triiodothyronine glucuronide and T4 sulfate. Endocrinology 125:2175-86.
52. Soars MG, Burchell B, Riley RJ. (2002). In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301:382-90.
53. Stockigt J. (2003). Assessment of thyroid function: towards an integrated laboratory-clinical approach. Clin Biochem Rev 24:109-22.
54. Szabo DT, Richardson VM, Ross DG, et al. (2009). Effects of perinatal PBDE exposure on hepatic phase I, phase II, phase III, and deiodinase 1 gene expression involved in thyroid hormone metabolism in male rat pups. Toxicol Sci 107:27-39.
55. Tong Z, Li H, Goljer I, et al. (2007). In vitro glucuronidation of thyroxine and triiodothyronine by liver microsomes and recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 35:2203-10.
56. Tuschl G, Mueller SO. (2006). Effects of cell culture conditions on primary rat hepatocytes-cell morphology and differential gene expression. Toxicology 218:205-15.
57. van der Deure WM, Hansen PS, Peeters RP, et al. (2008). Thyroid hormone transport and metabolism by organic anion transporter 1C1 and consequences of genetic variation. Endocrinology 149:5307-14.
58. van der Heide SM, Visser TJ, Everts ME, Klaren PH. (2002). Metabolism of thyroid hormones in cultured cardiac fibroblasts of neonatal rats. J Endocrinol 174:111-19.
59. Vansell NR, Klaassen CD. (2001). Increased biliary excretion of thyroxine by microsomal enzyme inducers. Toxicol Appl Pharmacol 176:187-94.
60. Vansell NR, Klaassen CD. (2002). Effect of microsomal enzyme inducers on the biliary excretion of triiodothyronine (T(3)) and its metabolites. Toxicol Sci 65:184-91.
61. Viollon-Abadie C, Bigot-Lasserre D, Nicod L, et al. (2000). Effects of model inducers on thyroxine UDP-glucuronosyl-transferase activity in vitro in rat and mouse hepatocyte cultures. Toxicol In Vitro 14: 505-12.
62. Visser TJ, Kaptein E, vanToor H, et al. (1993). Glucuronidation of thyroid hormone in rat liver: effects of in vivo treatment with microsomal enzyme inducers and in vitro assay conditions. Endocrinology 133: 2177-86.
63. Woody CJ, Weber SL, Laubach HE, et al. (1998). The effects of chronic exercise on metabolic and reproductive functions in male rats. Life Sci 62:327-32.
64. Yamanaka H, Nakajima M, Katoh M, Yokoi T. (2007). Glucuronidation of thyroxine in human liver, jejunum, and kidney microsomes. Drug Metab Dispos 35:1642-8.
65. Zhou T, Ross DG, DeVito MJ, Crofton KM. (2001). Effects of shortterm in vivo exposure to polybrominated diphenyl ethers on thyroid hormones and hepatic enzyme activities in weanling rats. Toxicol Sci 61:76-82.